Esophageal Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ESCR MCID: ESP021 MIFTS: 83	Esophageal Cancer (ESCR) Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Esophageal Cancer

MalaCards integrated aliases for Esophageal Cancer:

IMPROVED

Name: Esophageal Cancer ⁵⁷ ¹¹ ¹⁹ ⁷³ ¹² ⁵ ⁴¹ ¹⁴ ³⁶ ⁷⁵

Esophageal Carcinoma ¹¹ ⁵⁸ ⁵³ ¹⁴ ¹⁶ ⁷¹

Carcinoma of Esophagus ¹¹ ⁵⁸ ²⁸ ⁵

Esophageal Squamous Cell Carcinoma, Somatic ⁵⁷ ⁵

Esophageal Carcinoma, Somatic ⁵⁷ ⁵

Gastric Cardia Adenocarcinoma ⁷³ ⁷¹

Esophageal Neoplasms ⁴³ ⁷¹

Esophagus Cancer ¹¹ ¹⁹

Malignant Tumor of the Middle Third of the Esophagus ¹¹

Malignant Neoplasm of Proximal Third of Esophagus ¹¹

Malignant Neoplasm of Middle Third of Oesophagus ¹¹

Malignant Neoplasm of Distal Third of Esophagus ¹¹

Malignant Neoplasm of Lower Third of Oesophagus ¹¹

Malignant Neoplasm of Middle Third of Esophagus ⁷¹

Malignant Tumor of Proximal Third of Esophagus ¹¹

Malignant Tumor of Distal Third of Esophagus ¹¹

Malignant Neoplasm of Upper Third Esophagus ¹¹

Malignant Tumor of Abdominal Esophagus ¹¹

Squamous Cell Carcinoma of Esophagus ⁷¹

Esophageal Squamous Cell Carcinoma ⁷³

Malignant Neoplasm of Esophagus ⁷¹

Esophageal Cancer, Somatic ⁵⁷

Ca Middle Third Oesophagus ¹¹

Aerodigestive Tract Cancer ⁷³

Ca Lower Third Oesophagus ¹¹

Carcinoma of Oesophagus ¹¹

Cancer of Oesophagus ¹¹

Cancer of Esophagus ¹¹

Cancer, Esophageal ³⁸

Escc ⁷³

Escr ⁷³

Characteristics:

Inheritance:

Somatic mutation ⁵⁷

Prevelance:

Carcinoma of Esophagus: 1-9/100000 (Worldwide, Europe, Europe, United States, Worldwide, France, India, Africa, Japan, Russian Federation, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands) 1-5/10000 (Europe, United Kingdom, China, Latin America) 1-9/1000000 (Iran, Islamic Republic of) ⁵⁸

Age Of Onset:

Carcinoma of Esophagus: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of oesophagus

Malignant neoplasm: Lower third of oesophagus

Malignant neoplasm: Middle third of oesophagus

Malignant neoplasm: Oesophagus, unspecified

Malignant neoplasm: Upper third of oesophagus

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹¹ DOID:1107 DOID:5041

OMIM® ⁵⁷ 133239

ICD9CM ³⁴ 150.2 150.3 150.4 more

MeSH ⁴³ D004938

NCIt ⁴⁹ C3028 C3513 C3533 more

SNOMED-CT ⁶⁸ 126817006 187729008 255079005 more

ICD10 ³¹ C15 C15.3 C15.4 more

UMLS via Orphanet ⁷² C0014859 C0152018 C0546837

Orphanet ⁵⁸ ORPHA70482

MedGen ⁴⁰ C0152018 C0279626 C2751126 more

EFO ¹⁶ EFO_0002916

UMLS ⁷¹ C0014859 C0152018 C0153413 more

Sources

Summaries for Esophageal Cancer

OMIM®: ⁵⁷ Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide. Both environmental and genetic risk factors play a role in the pathogenesis of the disorder. In Europe and North America, heavy smoking, alcohol consumption, and increased body mass index (BMI) are the main environmental risk factors. In contrast, the particularly high incidence of ESCC in some areas of China, central Asia, and southern Africa is associated with nutritional deficiencies, high intake of nitrosamine-rich or pickled vegetables, and low socioeconomic status; smoking, alcohol consumption, and BMI play a lesser role in these populations. There is a tendency for familial aggregation of ESCC in high-risk geographic areas, suggesting a genetic component to increased susceptibility. Gastric cardia adenocarcinoma is another common type of cancer in China that shows similarities to ESCC in terms of geographic distribution and environmental risk factors (summary by Wang et al., 2010 and Abnet et al., 2010). (133239) (Updated 24-Oct-2022)

MalaCards based summary: Esophageal Cancer, also known as esophageal carcinoma, is related to esophagus squamous cell carcinoma and squamous cell carcinoma, and has symptoms including abdominal pain, constipation and coughing. An important gene associated with Esophageal Cancer is TGFBR2 (Transforming Growth Factor Beta Receptor 2), and among its related pathways/superpathways are Epithelial to mesenchymal transition in colorectal cancer and miRNAs involved in DNA damage response. The drugs Iron and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include esophagus, lymph node and lung, and related phenotypes are dysphagia and weight loss

GARD: ¹⁹ Esophageal cancer is a cancer of the esophagus, the hollow tube that carries foods and liquids from the throat to the stomach. Symptoms that may develop as the cancer grows include heartburn, pain when swallowing, difficulty swallowing, a hoarse voice, a cough that does not go away, weight loss, and coughing up blood. The exact cause of Esophageal cancer usually is not known, but both environmental and genetic factors are thought to play a role in its development. For example, variationss in any of several genes may cause susceptibility to Esophageal cancer. Environmental factors that may increase a person's chance to develop Esophageal cancer include tobacco use, heavy alcohol use, older age, obesity, and damage to the esophagus from acid reflux (Barrett esophagus). The diagnosis may be based on imaging studies and tests such as chest X-ray, upper endoscopy, and a biopsy of tissue from the esophagus.

MedlinePlus: ⁴¹ The esophagus is a hollow tube that carries food and liquids from your throat to your stomach. Early esophageal cancer usually does not cause symptoms. Later, you may have symptoms such as: Painful or difficult swallowing Weight loss A hoarse voice or cough that doesn't go away You're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. Your risk also goes up as you age Your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. Treatments include surgery, radiation, and chemotherapy. You might also need nutritional support, since the cancer or treatment may make it hard to swallow. NIH: National Cancer Institute

UniProtKB/Swiss-Prot: ⁷³ A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

Orphanet: ⁵⁸ Esophageal carcinoma (EC) is a tumor arising in the epithelial cells lining the esophagus and can be divided into two subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).

Disease Ontology ¹¹ Esophageal cancer: A gastrointestinal system cancer that is located in the esophagus.

Esophageal carcinoma: A esophageal cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: ⁷⁵ Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Sources

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1081)

#	Related Disease	Score	Top Affiliating Genes
1	esophagus squamous cell carcinoma	33.5	WWOX TGFBR2 RNF6 PVT1 HOTAIR CASC9
2	squamous cell carcinoma	32.9	WWOX TP53 TGFBR2 RNF6 HOTAIR CRNN
3	gastric cancer	32.3	ZEB2 TP53 TGFBR2 PVT1 MIR34A MIR21
4	head and neck cancer	32.1	TP53 MIR373 MIR34A MIR30E MIR21 MIR126
5	lung cancer	32.0	ZEB1 TP53 TGFBR2 PVT1 MIR373 MIR34A
6	esophageal disease	32.0	TP53 MIR34A MIR21 MIR126
7	squamous cell carcinoma, head and neck	31.9	TP53 TGFBR2 MIR373 MIR30E MIR21 MIR148A
8	hepatocellular carcinoma	31.8	ZEB2 ZEB1 TP53 TGFBR2 PVT1 MIR34A
9	pancreatic ductal adenocarcinoma	31.7	TP53 PVT1 MIR34A MIR30E MIR21 MIR148A
10	thoracic cancer	31.6	MIR373 MIR34A MIR30E MIR21 MIR148A MIR126
11	pancreatic cancer	31.6	ZEB2 ZEB1 TP53 TGFBR2 PVT1 MIR34A
12	gastrointestinal system disease	31.5	MIR34A MIR30E MIR21 MIR148A MIR126 MIR106A
13	leukemia, acute myeloid	31.4	ZEB1 TP53 MIR34A MIR30E MIR21 MIR126
14	lung cancer susceptibility 3	31.4	TP53 TGFBR2 MIR30E MIR21 MIR126 HOTAIR
15	connective tissue disease	31.4	TP53 TGFBR2 MIR373 MIR34A MIR30E MIR21
16	lymphatic system disease	31.4	TP53 MIR373 MIR34A MIR30E MIR21 MIR148A
17	pharynx cancer	31.4	MIR30E MIR21 MIR148A MIR126 MIR106A
18	oral squamous cell carcinoma	31.4	MIR373 MIR34A MIR30E MIR21 MIR148A MIR126
19	nasopharyngeal carcinoma	31.4	TP53 TGFBR2 PVT1 MIR30E MIR21 MIR148A
20	ovarian cancer	31.4	ZEB2 ZEB1 WWOX TP53 TGFBR2 PVT1
21	biliary tract cancer	31.4	TP53 TGFBR2 MIR373 MIR30E MIR21 MIR126
22	kidney cancer	31.4	TP53 PVT1 MIR21 MIR126 MIR106A HOTAIR
23	lymphoma, non-hodgkin, familial	31.3	TP53 MIR373 MIR34A MIR30E MIR21 MIR148A
24	breast cancer	31.3	ZEB1 WWOX TP53 TGFBR2 PVT1 MIR373
25	peripheral nervous system disease	31.3	TP53 MIR34A MIR30E MIR21 MIR126
26	gallbladder cancer	31.3	TP53 TGFBR2 MIR373 MIR30E MIR126 HOTAIR
27	type 2 diabetes mellitus	31.2	TP53 PVT1 MIR34A MIR30E MIR21 MIR148A
28	colonic benign neoplasm	31.2	TP53 TGFBR2 MIR21
29	renal cell carcinoma, nonpapillary	31.2	ZEB2 ZEB1 TP53 TGFBR2 PVT1 MIR34A
30	retinitis pigmentosa 11	31.2	ZEB1 TP53 PVT1 MIR126 HOTAIR
31	rectum cancer	31.1	TP53 MIR21 MIR126
32	thyroid cancer, nonmedullary, 1	31.1	TP53 PVT1 HOTAIR
33	brain cancer	31.1	TP53 MIR34A MIR21 MIR126
34	cervical cancer	31.0	TP53 PVT1 MIR34A MIR21 HOTAIR
35	body mass index quantitative trait locus 11	31.0	TP53 MIR34A MIR30E MIR21 MIR148A MIR126
36	cholangiocarcinoma	31.0	TP53 MIR373 MIR21 MIR148A
37	bone marrow cancer	31.0	TP53 MIR34A MIR21 MIR148A MIR126
38	dermatomyositis	31.0	MIR34A MIR21 MIR148A
39	glioma	31.0	TP53 PVT1 MIR34A MIR21 HOTAIR
40	stomach disease	31.0	MIR34A MIR21 MIR148A MIR126 MIR106A
41	prostate cancer	30.9	ZEB1 TP53 TGFBR2 PVT1 MIR34A MIR21
42	gastrointestinal system cancer	30.9	MIR34A MIR30E MIR21 MIR148A MIR126 MIR106A
43	leukemia, chronic lymphocytic	30.9	TP53 MIR373 MIR34A MIR30E MIR21 MIR16-2
44	oral cavity cancer	30.9	MIR373 MIR21 MIR126 MIR106A
45	central nervous system cancer	30.9	TP53 MIR34A MIR30E MIR21 MIR148A MIR126
46	immune system disease	30.8	MIR34A MIR30E MIR21 MIR148A MIR126 MIR106A
47	hematologic cancer	30.8	PVT1 MIR34A MIR21 MIR148A MIR126 MIR106A
48	aortic valve disease 2	30.8	MIR34A MIR21 MIR126
49	small cell cancer of the lung	30.8	TP53 MIR21 HOTAIR
50	glioma susceptibility 1	30.8	TP53 MIR21 MIR106A

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease	Deficiency Anemia
Esophageal Disease	Esophagitis
Familial Atrial Fibrillation	Heart Disease
Neutropenia	Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:

Sources

Symptoms & Phenotypes for Esophageal Cancer

Human phenotypes related to Esophageal Cancer:

⁵⁸ ³⁰ (show all 14)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	dysphagia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002015
2	weight loss ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001824
3	recurrent singultus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100247
4	gastroesophageal reflux ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002020
5	abnormality of the voice ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001608
6	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012735
7	abnormality of the neck ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000464
8	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100749
9	lymphadenopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002716
10	obesity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001513
11	abnormal intestine morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002242
12	barrett esophagus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100580
13	esophageal neoplasm ⁵⁸		Very frequent (99-80%)
14	esophageal carcinoma ³⁰			HP:0011459

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 24-Oct-2022)

Neoplasia:
esophageal cancer
esophageal squamous cell carcinoma

Clinical features from OMIM®:

133239 (Updated 24-Oct-2022)

UMLS symptoms related to Esophageal Cancer:

abdominal pain; constipation; coughing; diarrhea; dyspepsia; heartburn; icterus; nausea and vomiting; snoring; tinnitus; sore throat; vertigo/dizziness; equilibration disorder; gastrointestinal gas

GenomeRNAi Phenotypes related to Esophageal Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 24)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-104	9.74	CRNN
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-113	9.74	WWOX
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-114	9.74	ZEB2
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	9.74	TP53
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.74	TP53
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.74	WWOX
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	9.74	TP53
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-145	9.74	WWOX
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-164	9.74	WWOX
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	9.74	TP53 WWOX
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-178	9.74	CRNN
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-184	9.74	TP53
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.74	TP53 WWOX
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.74	TP53
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-20	9.74	TP53
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	9.74	CRNN
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-28	9.74	CRNN
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	9.74	TP53
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	9.74	TP53
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-62	9.74	TP53
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.74	WWOX
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.74	ZEB2
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.74	CRNN
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-86	9.74	WWOX

MGI Mouse Phenotypes related to Esophageal Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	pigmentation	MP:0001186	9.55	DCC TGFBR2 TP53 ZEB1 ZEB2
2	neoplasm	MP:0002006	9.5	DCC LZTS1 MIR34A TGFBR2 TP53 WWOX
3	no phenotypic analysis	MP:0003012	9.17	HOTAIR MIR126 MIR30E MIR34A TP53 WWOX

Sources

Drugs & Therapeutics for Esophageal Cancer

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 498)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved

Phase 4

7439-89-6

29936

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Levobupivacaine

Approved, Investigational

Phase 4

27262-47-1

92253

Pravastatin

Approved

Phase 4

81093-37-0

54687

Iron isomaltoside 1000

Approved, Investigational

Phase 4

1370654-58-2

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Nicotine

Approved

Phase 4

54-11-5

942 89594

Oxymetazoline

Approved, Investigational

Phase 4

1491-59-4

4636

Phenylephrine

Approved

Phase 4

59-42-7

6041

Dobutamine

Approved

Phase 4

34368-04-2

36811

Norepinephrine

Approved

Phase 4

51-41-2

439260

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Nedaplatin

Approved, Investigational

Phase 4

95734-82-0

Lipid Regulating Agents

Phase 4

Hypolipidemic Agents

Phase 4

Anticholesteremic Agents

Phase 4

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Analgesics

Phase 4

Central Nervous System Stimulants

Phase 4

Anesthetics

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Anti-Inflammatory Agents

Phase 4

Cholinergic Agents

Phase 4

Nicotinic Agonists

Phase 4

Vasoconstrictor Agents

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Dopamine Agents

Phase 4

Neuromuscular Nondepolarizing Agents

Phase 4

Neuromuscular Blocking Agents

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

FOLFIRINOX

Phase 4

Menthol

Approved, Experimental

Phase 3

1490-04-6, 2216-51-5, 15356-60-2

1254 16666 165675

Trioxsalen

Approved

Phase 3

3902-71-4

5585

Cobalt

Approved, Experimental

Phase 3

7440-48-4

104729

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Chlorpheniramine

Approved

Phase 3

113-92-8, 132-22-9

2725

Ranitidine

Approved, Withdrawn

Phase 3

66357-59-3, 82530-72-1, 66357-35-5

3001055 5039

Ethanol

Approved

Phase 3

64-17-5

702

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Durvalumab

Approved, Investigational

Phase 3

1428935-60-7

Sevoflurane

Approved, Vet_approved

Phase 3

28523-86-6

5206

Propofol

Approved, Investigational, Vet_approved

Phase 3

2078-54-8

4943

Dezocine

Approved, Investigational

Phase 3

53648-55-8

3033053

Pertuzumab

Approved

Phase 3

380610-27-5

Sucralfate

Approved

Phase 3

54182-58-0

Curcumin

Approved, Investigational

Phase 3

458-37-7, 84765-67-3

969516

Interventional clinical trials:

(show top 50) (show all 1719)

#	Name	Status	NCT ID	Phase	Drugs
1	A Clinical Study of Endostar Combined With TP Regimen for Chemoradiotherapy in Esophageal Cancer	Unknown status	NCT04164797	Phase 4	endostar+chemoradiotherapy
2	Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer	Unknown status	NCT00628784	Phase 4
3	Postoperative Pain Management After Minimally Invasive Esophagectomy	Unknown status	NCT02042313	Phase 4
4	H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients	Unknown status	NCT03642093	Phase 4
5	Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy	Unknown status	NCT00790140	Phase 4
6	Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX	Unknown status	NCT02609425	Phase 4
7	Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity	Unknown status	NCT04269369	Phase 4	5-Fluorouracil
8	Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer	Unknown status	NCT01038154	Phase 4	Pravastatin
9	An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma	Unknown status	NCT01927328	Phase 4	Iron isomaltoside 1000
10	A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma	Unknown status	NCT00642239	Phase 4	placebo;Sodium Glycididazole
11	Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer	Completed	NCT00333099	Phase 4
12	A STUDY OF CRYOSPRAY ABLATIONTM USING SURGICAL RESECTION SPECIMENS TO DETERMINE TREATMENT EFFECT, DEPTH OF INJURY, AND SIDE EFFECTS IN THE ESOPHAGUS (CSA Depth 3)	Completed	NCT00754468	Phase 4
13	Perioperative Goal Directed Fluid Therapy During Esophageal Resection A Prospective Randomized Controlled Open Multi-centre Trial to Study the Effect on Postoperative Complications	Completed	NCT01416077	Phase 4
14	Enhancing Tobacco Use Treatment for African American Light Smokers	Completed	NCT00666978	Phase 4	bupropion hydrochloride
15	Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients	Completed	NCT01962272	Phase 4
16	Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer	Completed	NCT00911092	Phase 4	Chemotherapy (Fluorouracil and Cisplatin)
17	Comparing the Lozenge to the Patch for Smoking Cessation	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
18	Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
19	A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy	Completed	NCT02320734	Phase 4	Rocuronium
20	Multicenter Comparative of Toxicity and Effectiveness of Lobaplation or Cisplatin Based Adjuvant Chemotherapy in Esophageal Carcinoma	Completed	NCT03413436	Phase 4	Lobaplatin;Cisplatin
21	A Perspective Random Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma	Completed	NCT02721563	Phase 4	Sodium Glycididazole;Placebo
22	Clinical and Medico-economic Evaluation of Radiofrequency Ablation Versus Oesophagectomy in the Treatment of High Grade Dysplasia in Barrett's Oesophagus	Completed	NCT02558504	Phase 4
23	Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study	Completed	NCT02426034	Phase 4	ApatinibTablets
24	Thromboprophylaxis in Oesophageal Cancer Patients - A Randomized, Controlled Trial	Recruiting	NCT05067153	Phase 4	Fragmin 5000 UNT in 0.2 ML Prefilled Syringe
25	PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
26	A Perspective Trial of Sodium Glycididazole Combined With Concurrent Chemoradiotherapy for Locally Recurrent Squamous Cell Esophageal Carcinoma	Terminated	NCT02721576	Phase 4	Sodium Glycididazole
27	A Perspective Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma	Terminated	NCT02721550	Phase 4	Sodium Glycididazole
28	Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;	Unknown status	NCT01745107	Phase 3
29	Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer	Unknown status	NCT02607540	Phase 3
30	Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer	Unknown status	NCT02025036	Phase 3	Capecitabine(Aibin);Oxaliplatin(Aiheng)
31	Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy	Unknown status	NCT02603159	Phase 3	Capecitabine(Aibin)
32	PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial	Unknown status	NCT03691090	Phase 3	SHR-1210;Placebo;paclitaxel;cisplatin
33	An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric	Unknown status	NCT03285906	Phase 2, Phase 3	Apatinib
34	Self-Expandable Esophageal Radiation Stent:a Multicentric Randomized Controlled Trial in Patients With Advanced Esophageal Cancer	Unknown status	NCT01054274	Phase 3
35	A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P02	Unknown status	NCT03308552	Phase 3	Paclitaxel;Platinum-Based Drug
36	Randomized Control Study on Surgical Treatment for Middle and Lower Thoracic Esophageal Cancer Patients Without Upper Mediastinal Lymph Node Metastasis Through Left Versus Right Transthoracic Approach	Unknown status	NCT02448979	Phase 3
37	Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer: a Multi-center, Randomized, and Open-label Trial	Unknown status	NCT02355249	Phase 3
38	Randomized Study of Intrathoracic Side-to-side Stapled Esophagogastric Anastomosis Versus Circular-Stapled Technique in Ivor-Lewis Oesophagectomy	Unknown status	NCT01242124	Phase 2, Phase 3
39	A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma	Unknown status	NCT02570893	Phase 3	Paclitaxel and carboplatin
40	Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.	Unknown status	NCT00686114	Phase 3	Paclitaxel;Cisplatin;Tarceva
41	A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	Unknown status	NCT00357682	Phase 3	Esomeprazole;Aspirin
42	A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY	Unknown status	NCT00002884	Phase 3	chemotherapy;cisplatin;fluorouracil
43	A Phase Ⅲ Study of Respiratory Complications Associated With Esophagectomy Through Either Ivor-Lewis or Sweet Approach for the Treatment of Middle or Lower Third Intrathoracic Esophageal Carcinoma	Unknown status	NCT01053182	Phase 3
44	A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus	Unknown status	NCT00041262	Phase 3	cisplatin;epirubicin hydrochloride;fluorouracil
45	Efficacy of Nasogastric Tube Application in Postoperative Care of Esophagectomy: a Randomized Clinical Trial	Unknown status	NCT03273686	Phase 3
46	A Randomised Phase II/III Multi-Centre Clinical Trial of Definitive Chemotherapy, With or Without Cetuximab, in Carcinoma of the Oesophagus	Unknown status	NCT00509561	Phase 2, Phase 3	capecitabine;cisplatin
47	A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma	Unknown status	NCT01216527	Phase 3
48	A Prospective, Randomised Phase 3 Study of High-dose Versus Standard-dose Radiation of Inoperable Esophageal Carcinoma Treated With Concurrent Chemoradiation	Unknown status	NCT01937208	Phase 3	concurrent chemotherapy with radiation
49	Phase 3 Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma	Unknown status	NCT01034683	Phase 3	lobaplatin , 5-FU ,leucovorin
50	Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma	Unknown status	NCT02891083	Phase 3	Adjuvant chemotherapy (Paclitaxel and Cisplatin)

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carboplatin

Cisplatin

CISPLATIN PWDR

Methotrexate

Methotrexate Sodium

PROFIMER SODIUM

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Esophageal Cancer cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Esophageal Cancer:

Tumor infiltrating lymphocytes (TILs) for solid tumors

Embryonic/Adult Cultured Cells Related to Esophageal Cancer:

Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: esophageal neoplasms

Sources

Genetic Tests for Esophageal Cancer

Genetic tests related to Esophageal Cancer:

#	Genetic test	Affiliating Genes
1	Carcinoma of Esophagus ²⁸

Sources

Anatomical Context for Esophageal Cancer

Organs/tissues related to Esophageal Cancer:

FMA: Esophagus

MalaCards : Lymph Node, Lung, T Cells, Bone Marrow, Liver, Testis, Breast

Sources

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 35988)

#	Title	Authors	PMID	Year
1	Identification of somatic mutations of the RNF6 gene in human esophageal squamous cell carcinoma. ⁶² ⁵⁷ ⁵	Lo HS...Lee MP	12154016	2002
2	Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. ⁶² ⁵⁷	Wu C...Lin D	22960999	2012
3	A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. ⁶² ⁵⁷	Abnet CC...Taylor PR	20729852	2010
4	Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. ⁶² ⁵⁷	Wang LD...Zhang XJ	20729853	2010
5	Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. ⁶² ⁵⁷	Lo PH...Lung ML	16799631	2007
6	Gefitinib-sensitizing mutations in esophageal carcinoma. ⁶² ⁵	Guo M...Lu F	16707764	2006
7	An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma. ⁶² ⁵⁷	Wang S...Meltzer SJ	12545169	2003
8	Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. ⁶² ⁵	Kuroki T...Croce CM	11956080	2002
9	Allelic loss on chromosome bands 13q11-q13 in esophageal squamous cell carcinoma. ⁶² ⁵⁷	Li G...Emmert-Buck MR	11433530	2001
10	Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. ⁶² ⁵⁷	Kawakami K...Meltzer SJ	11078757	2000
11	Segregation analysis of esophageal cancer in a moderately high-incidence area of northern China. ⁶² ⁵⁷	Zhang W...Wu M	10841811	2000
12	A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma. ⁵³ ⁵	Tanaka S...Sugimachi K	10789724	2000
13	Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population. ⁶² ⁵⁷	Hu N...Taylor PR	10679910	2000
14	Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. ⁶² ⁵⁷	Boynton RF...Meltzer SJ	1913694	1991
15	Predictive Model of Chemotherapy-Induced Myelosuppression for Patients with Esophageal Cancer. ⁶² ⁴¹	Zheng Z...Zhang Y	36134707	2022
16	Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer. ⁵	Manoharan V...Lunec J	30816478	2019
17	Integrated genomic characterization of oesophageal carcinoma. ⁵⁷	Cancer Genome Atlas Research Network...Project Team: National Institutes of Health	28052061	2017
18	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
19	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
20	Prognostic significance of differentially expressed miRNAs in esophageal cancer. ⁶² ⁴⁶	Hu Y...Xu XC	20309880	2011
21	MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. ⁶² ⁴⁶	Hummel R...Watson DI	20628822	2011
22	SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. ⁵⁷	Bass AJ...Meyerson M	19801978	2009
23	MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. ⁶² ⁴⁶	Mathe EA...Harris CC	19789312	2009
24	MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. ⁶² ⁴⁶	Lee KH...Lu PJ	19501585	2009
25	Multiple roles for Sox2 in the developing and adult mouse trachea. ⁵⁷	Que J...Hogan BL	19403656	2009
26	Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. ⁵⁷	Morrison BH...Lindner DJ	19430495	2009
27	MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. ⁶² ⁴⁶	Hiyoshi Y...Baba H	19276261	2009
28	MicroRNA expression profiles of esophageal cancer. ⁶² ⁴⁶	Feber A...Litle VR	18242245	2008
29	Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. ⁶² ⁴⁶	Guo Y...He J	18172293	2008
30	Multiple dose-dependent roles for Sox2 in the patterning and differentiation of anterior foregut endoderm. ⁵⁷	Que J...Hogan BL	17522155	2007
31	Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. ⁵⁷	Wei D...Xie K	15930301	2005
32	Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. ⁵⁷	Berman DM...Beachy PA	14520411	2003
33	Causal relationship between the loss of RUNX3 expression and gastric cancer. ⁵⁷	Li QL...Ito Y	11955451	2002
34	The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. ⁵	Ishii H...Croce CM	10097140	1999
35	Accumulation of genetic alterations during esophageal carcinogenesis. ⁵⁷	Mori T...Nakamura Y	7874113	1994
36	Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. ⁵	Miyake S...Yuasa Y	8187090	1994
37	Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. ⁵⁷	Boynton RF...Meltzer SJ	1565631	1992
38	17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. ⁵⁷	Blount PL...Reid BJ	1680552	1991
39	Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. ⁵⁷	Sano T...Tahara E	2032230	1991
40	Efficacy and Safety Analysis of Submucosal Tunnel Endoscopic Resection for Submucosal Masses in Esophageal Muscularis Propria. ⁴¹	Liu Q...Li J	36199767	2022
41	Clinical Comparison of Endoscopic Ultrasonography and CT in Preoperative TN Staging of Esophagogastric Junction Cancer. ⁴¹	Peng T...Li S	36128174	2022
42	Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. ⁵³ ⁶²	Brun R...Vlodavsky I	19749739	2009
43	Aberrant promoter methylation and reduced expression of p16 gene in esophageal squamous cell carcinoma from Kashmir valley: a high-risk area. ⁵³ ⁶²	Salam I...Das BC	19513816	2009
44	Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status. ⁵³ ⁶²	Ma G...Tagawa M	19363469	2009
45	Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. ⁵³ ⁶²	Hoffmann AC...Brabender J	19259700	2009
46	Activation of NFAT signal by p53-K120R mutant. ⁵³ ⁶²	Shinmen N...Hiwasa T	19416725	2009
47	p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. ⁵³ ⁶²	Cescon DW...Liu G	19383811	2009
48	Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. ⁵³ ⁶²	Zhuo WL...Chen ZT	19427967	2009
49	Upregulation of matrix metalloproteinase-1 (MMP-1) expression in oral carcinomas of betel quid (BQ) users: roles of BQ ingredients in the acceleration of tumour cell motility through MMP-1. ⁵³ ⁶²	Lee CH...Liu YC	18571622	2008
50	Activin A enhances MMP-7 activity via the transcription factor AP-1 in an esophageal squamous cell carcinoma cell line. ⁵³ ⁶²	Yoshinaga K...Mori M	18695873	2008

Sources

Genes for Esophageal Cancer

Genes/enhancers related to Esophageal Cancer (15 elite genes):

(show top 50) (show all 311)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	1255.11	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	10789724
2	WWOX	WW Domain Containing Oxidoreductase	Protein Coding	942.12	Molecular basis known ⁵⁷ Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders (show sections)	11956080
3	LZTS1	Leucine Zipper Tumor Suppressor 1	Protein Coding	924.44	Molecular basis known ⁵⁷ Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Gene name (show sections)	10097140
4	RNF6	Ring Finger Protein 6	Protein Coding	907.63	Molecular basis known ⁵⁷ Pathogenic ⁵ GeneCards inferred via : Disorders (show sections)	12154016
5	DCC	DCC Netrin 1 Receptor	Protein Coding	903.33	Molecular basis known ⁵⁷ Pathogenic ⁵ DISEASES inferred ¹⁴	8187090
6	TP53	Tumor Protein P53	Protein Coding	466.14	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	30816478 26619011 12168111 (more) 15386362 9028350 9813975 9797131 11961303 11911308 9655287 8467510 8722219 7549269 8609696 15639342 10928129 11388392 9209522 19363469 8608498 7827889 10541972 7720492 15693850 16116499 8732116 10522005 9808524 1396069 8280379 1358781 7656818 9635853 10102609 8054284 1519662 11783017 11968758 10960772 9311588 9066606 7589997 17708270 15771621 11562772 9306559 16734736 16525665 15946564 16127293 12823209 11508622 10791203 10753186 9779600 14641293 11850840 9066744 7539243 7813357 17760650 16572897 7887653 7915093 8044781 15305417 7522040 8506620 16488074 16201092 10466045 2263646 19383811 18207033 10759947 10761706 9649454 8907205 10526265 8055646 8166440 11042560 12670524 19416725
7	MIR21	MicroRNA 21	RNA Gene	426.97	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19276261 19789312
8	MIR30E	MicroRNA 30e	RNA Gene	367.71	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	20309880
9	MIR148A	MicroRNA 148a	RNA Gene	366.44	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	20628822
10	MIR373	MicroRNA 373	RNA Gene	366.16	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19501585
11	MIR34A	MicroRNA 34a	RNA Gene	364.03	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	20309880
12	MIR126	MicroRNA 126	RNA Gene	362.57	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	20309880
13	MIR16-2	MicroRNA 16-2	RNA Gene	359.3	Causal ⁴⁶ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	20309880
14	MIR106A	MicroRNA 106a	RNA Gene	359.03	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	20628822
15	CRNN	Cornulin	Protein Coding	324.63	Causative variation ⁷³ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
16	ZEB1	Zinc Finger E-Box Binding Homeobox 1	Protein Coding	162.21	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	28635228
17	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	161.29	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴ ¹⁴	28441714
17	HOTAIR::GH12J053962	TSS distance: +8.3kb Elite enhancer with elite association with HOTAIR			Curated enhancer-disease association ²³ ¹³	24788237
18	ZEB2	Zinc Finger E-Box Binding Homeobox 2	Protein Coding	160.86	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	28635228
19	CASC9	Cancer Susceptibility 9	RNA Gene	160.62	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	27431358
20	PVT1	Pvt1 Oncogene	RNA Gene	160.45	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	27698800
21	UCA1	Urothelial Cancer Associated 1	RNA Gene	160.39	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	16914571 27667646
22	GAS5	Growth Arrest Specific 5	RNA Gene	159.46	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	29386089
23	PSPC1-AS2	PSPC1 Antisense RNA 2	RNA Gene	159.25	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	27714034
24	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	159.24	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	25646744
25	PCAT1	Prostate Cancer Associated Transcript 1	RNA Gene	158.67	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	29314203
26	CASC2	Cancer Susceptibility 2	RNA Gene	158.59	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	28964779
27	LINC02098	Long Intergenic Non-Protein Coding RNA 2098	RNA Gene	158.51	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	27714034
28	LINC01554	Long Intergenic Non-Protein Coding RNA 1554	RNA Gene	157.72	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	28028307
29	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	157.18	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	27470544 27777857 28635228
30	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	RNA Gene	157.17	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	16965397
31	POLR2E	RNA Polymerase II, I And III Subunit E	Protein Coding	156.92	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	25874495
32	C20orf204	Chromosome 20 Open Reading Frame 204	Protein Coding	155.9	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	28028307
33	SCAT1	S-Phase Cancer Associated Transcript 1	RNA Gene	154.39	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28028307
34	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	154.26	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	9422992
35	PEG10	Paternally Expressed 10	Protein Coding	154.17	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25591808
36	LINC02155	Long Intergenic Non-Protein Coding RNA 2155	RNA Gene	154.11	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28028307
37	LINC02156	Long Intergenic Non-Protein Coding RNA 2156	RNA Gene	154.11	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28028307
38	LINC02157	Long Intergenic Non-Protein Coding RNA 2157	RNA Gene	154.11	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28028307
39	LINC00365	Long Intergenic Non-Protein Coding RNA 365	RNA Gene	153.83	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28028307
40	MEG3	Maternally Expressed 3	RNA Gene	152.92	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28539329
41	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	8564957 21489289 26171017
42	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	25874495
43	LINC02154	Long Intergenic Non-Protein Coding RNA 2154	RNA Gene	150	Experimental evidence: Regulation ³⁷	28028307
44	MIR223	MicroRNA 223	RNA Gene	63.85	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	19789312
45	MIR192	MicroRNA 192	RNA Gene	62.96	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	19789312
46	MIR375	MicroRNA 375	RNA Gene	61.37	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19789312
47	MIR205	MicroRNA 205	RNA Gene	61.2	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18242245
48	MIR107	MicroRNA 107	RNA Gene	59.52	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	18172293
49	MIR203A	MicroRNA 203a	RNA Gene	59.04	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	19789312
50	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	52.27	Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	26619011 9414383 11776828 (more) 16163549 15612883 9149125 19513816 9311588 11815963 7880531 7547637 8595411 9759649 10921045 15946564

Sources

Variations for Esophageal Cancer

ClinVar genetic disease variations for Esophageal Cancer:

IMPROVED

⁵ (show top 50) (show all 154)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	WWOX	NM_016373.4(WWOX):c.1056G>C (p.Met352Ile)	SNV	Pathogenic	1686306		GRCh37: 16:78466649-78466649 GRCh38: 16:78432752-78432752
2	TP53	NM_000546.6(TP53):c.298del (p.Gln100fs)	DEL	Pathogenic	634674	rs1567556006	GRCh37: 17:7579389-7579389 GRCh38: 17:7676071-7676071
3	LZTS1	NM_021020.5(LZTS1):c.85T>C (p.Ser29Pro)	SNV	Pathogenic	4245	rs28937897	GRCh37: 8:20112608-20112608 GRCh38: 8:20255097-20255097
4	LZTS1	NM_021020.5(LZTS1):c.355A>G (p.Lys119Glu)	SNV	Pathogenic	4246	rs119473032	GRCh37: 8:20111087-20111087 GRCh38: 8:20253576-20253576
5	WWOX	NM_016373.4(WWOX):c.872T>C (p.Leu291Pro)	SNV	Pathogenic	5203	rs119487098	GRCh37: 16:78466465-78466465 GRCh38: 16:78432568-78432568
6	RNF6	NM_005977.4(RNF6):c.305G>A (p.Arg102Lys)	SNV	Pathogenic	5700	rs121434522	GRCh37: 13:26789714-26789714 GRCh38: 13:26215577-26215577
7	RNF6	NM_005977.4(RNF6):c.724G>A (p.Ala242Thr)	SNV	Pathogenic	5701	rs121434523	GRCh37: 13:26789295-26789295 GRCh38: 13:26215158-26215158
8	RNF6	NM_005977.4(RNF6):c.731G>A (p.Gly244Asp)	SNV	Pathogenic	5702	rs121434524	GRCh37: 13:26789288-26789288 GRCh38: 13:26215151-26215151
9	DCC	NM_005215.4(DCC):c.503T>C (p.Met168Thr)	SNV	Pathogenic	17075	rs121912967	GRCh37: 18:50432504-50432504 GRCh38: 18:52906134-52906134
10	TP53	NM_000546.6(TP53):c.628_639del (p.Asn210_Arg213del)	DEL	Pathogenic	984966	rs2073329654	GRCh37: 17:7578210-7578221 GRCh38: 17:7674892-7674903
11	WWOX	NM_016373.4(WWOX):c.790C>T (p.Arg264Ter)	SNV	Pathogenic	241105	rs756762196	GRCh37: 16:78458951-78458951 GRCh38: 16:78425054-78425054
12	TP53	NM_000546.6(TP53):c.583A>T (p.Ile195Phe)	SNV	Pathogenic Likely Pathogenic	376617	rs942158624	GRCh37: 17:7578266-7578266 GRCh38: 17:7674948-7674948
13	WWOX	NM_016373.4(WWOX):c.689A>C (p.Gln230Pro)	SNV	Pathogenic	813767		GRCh37: 16:78458850-78458850 GRCh38: 16:78424953-78424953
14	TP53	NM_000546.6(TP53):c.524G>A (p.Arg175His)	SNV	Pathogenic	12374	rs28934578	GRCh37: 17:7578406-7578406 GRCh38: 17:7675088-7675088
15	TGFBR2	NM_003242.6(TGFBR2):c.1576G>C (p.Glu526Gln)	SNV	Pathogenic	12503	rs121918714	GRCh37: 3:30732963-30732963 GRCh38: 3:30691471-30691471
16	TGFBR2	NM_003242.6(TGFBR2):c.1483C>T (p.Arg495Ter)	SNV	Pathogenic	12519	rs104893819	GRCh37: 3:30729962-30729962 GRCh38: 3:30688470-30688470
17	TGFBR2	NM_003242.6(TGFBR2):c.1134G>C (p.Arg378Ser)	SNV	Pathogenic	1028591	rs1575158079	GRCh37: 3:30713809-30713809 GRCh38: 3:30672317-30672317
18	TGFBR2	NM_003242.6(TGFBR2):c.1447del (p.Cys483fs)	DEL	Pathogenic	1686258		GRCh37: 3:30729926-30729926 GRCh38: 3:30688434-30688434
19	TGFBR2	NM_003242.6(TGFBR2):c.1561T>C (p.Trp521Arg)	SNV	Pathogenic	811253	rs1575166666	GRCh37: 3:30732948-30732948 GRCh38: 3:30691456-30691456
20	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Likely Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
21	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)	SNV	Likely Pathogenic Likely Pathogenic	12613	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
22	TP53	NM_000546.6(TP53):c.643A>G (p.Ser215Gly)	SNV	Likely Pathogenic	265337	rs886039484	GRCh37: 17:7578206-7578206 GRCh38: 17:7674888-7674888
23	CDKN2A	NM_000077.5(CDKN2A):c.239G>A (p.Arg80Gln)	SNV	Likely Pathogenic	376385	rs1057519883	GRCh37: 9:21971119-21971119 GRCh38: 9:21971120-21971120
24	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
25	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Likely Pathogenic Likely Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
26	PIK3CA	NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys)	SNV	Likely Pathogenic Likely Pathogenic	31944	rs121913273	GRCh37: 3:178936082-178936082 GRCh38: 3:179218294-179218294
27	TP53	NM_000546.6(TP53):c.451C>T (p.Pro151Ser)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	12370	rs28934874	GRCh37: 17:7578479-7578479 GRCh38: 17:7675161-7675161
28	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Likely Pathogenic Likely Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
29	SMAD4	NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)	SNV	Likely Pathogenic Likely Pathogenic	24832	rs377767347	GRCh37: 18:48591919-48591919 GRCh38: 18:51065549-51065549
30	PIK3CA	NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)	SNV	Likely Pathogenic Likely Pathogenic	13653	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
31	TP53	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	12365	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
32	SMAD4	NM_005359.6(SMAD4):c.1157G>A (p.Gly386Asp)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	8545	rs121912580	GRCh37: 18:48593406-48593406 GRCh38: 18:51067036-51067036
33	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
34	SMAD4	NM_005359.6(SMAD4):c.1081C>T (p.Arg361Cys)	SNV	Likely Pathogenic Likely Pathogenic	8543	rs80338963	GRCh37: 18:48591918-48591918 GRCh38: 18:51065548-51065548
35	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
36	TP53	NM_000546.6(TP53):c.731G>A (p.Gly244Asp)	SNV	Likely Pathogenic Likely Pathogenic	372785	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
37	TP53	NM_000546.6(TP53):c.638G>A (p.Arg213Gln)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	135359	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
38	TP53	NM_000546.6(TP53):c.832C>A (p.Pro278Thr)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376643	rs17849781	GRCh37: 17:7577106-7577106 GRCh38: 17:7673788-7673788
39	TGFBR2	NM_003242.6(TGFBR2):c.1355T>C (p.Leu452Pro)	SNV	Likely Pathogenic	930524	rs1699393884	GRCh37: 3:30715697-30715697 GRCh38: 3:30674205-30674205
40	WWOX	NM_016373.4(WWOX):c.108-2A>T	SNV	Likely Pathogenic	804478	rs1597207802	GRCh37: 16:78142318-78142318 GRCh38: 16:78108421-78108421
41	TP53	NM_000546.6(TP53):c.713G>A (p.Cys238Tyr)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	182935	rs730882005	GRCh37: 17:7577568-7577568 GRCh38: 17:7674250-7674250
42	TP53	NM_000546.6(TP53):c.404G>A (p.Cys135Tyr)	SNV	Likely Pathogenic Likely Pathogenic	141762	rs587781991	GRCh37: 17:7578526-7578526 GRCh38: 17:7675208-7675208
43	TP53	NM_000546.6(TP53):c.518T>C (p.Val173Ala)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376017	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
44	TP53	NM_000546.6(TP53):c.709A>G (p.Met237Val)	SNV	Likely Pathogenic	182934	rs730882004	GRCh37: 17:7577572-7577572 GRCh38: 17:7674254-7674254
45	TP53	NM_000546.6(TP53):c.578A>C (p.His193Pro)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376612	rs786201838	GRCh37: 17:7578271-7578271 GRCh38: 17:7674953-7674953
46	TP53	NM_000546.6(TP53):c.641A>G (p.His214Arg)	SNV	Likely Pathogenic Likely Pathogenic	376615	rs1057519992	GRCh37: 17:7578208-7578208 GRCh38: 17:7674890-7674890
47	TP53	NM_000546.6(TP53):c.613T>C (p.Tyr205His)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376685	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
48	TP53	NM_000546.6(TP53):c.824G>C (p.Cys275Ser)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376583	rs863224451	GRCh37: 17:7577114-7577114 GRCh38: 17:7673796-7673796
49	TP53	NM_000546.6(TP53):c.845G>A (p.Arg282Gln)	SNV	Likely Pathogenic Likely Pathogenic	237956	rs730882008	GRCh37: 17:7577093-7577093 GRCh38: 17:7673775-7673775
50	TP53	NM_000546.6(TP53):c.536A>G (p.His179Arg)	SNV	Likely Pathogenic Likely Pathogenic Likely Pathogenic	376606	rs1057519991	GRCh37: 17:7578394-7578394 GRCh38: 17:7675076-7675076

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	CRNN	p.Gly480Ser	VAR_048471	rs3829868
2	TGFBR2	p.Glu526Gln	VAR_015816	rs121918714

Cosmic variations for Esophageal Cancer:

⁸ (show top 50) (show all 33598)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM142081527	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1006+2T>A	p.?	19:58086172-58086172	22
2	COSM140961271	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.838+2T>A	p.?	19:58086172-58086172	22
3	COSM109468109	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.433+2T>A	p.?	19:58086172-58086172	22
4	COSM86897778	ZSCAN18	oesophagus,NS,carcinoma,squamous cell carcinoma	c.838+2T>A	p.?	19:58086172-58086172	22
5	COSM98059731	ZNF831	oesophagus,NS,carcinoma,squamous cell carcinoma	c.605T>C	p.L202P	20:59191624-59191624	22
6	COSM149923539	ZNF831	oesophagus,NS,carcinoma,squamous cell carcinoma	c.605T>C	p.L202P	20:59191624-59191624	22
7	COSM88515958	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.938C>G	p.S313C	17:82831517-82831517	22
8	COSM88515712	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.668C>G	p.S223*	17:82831787-82831787	22
9	COSM138690836	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-31C>G	p.?	17:82831517-82831517	22
10	COSM88513307	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.170C>G	p.S57*	17:82832285-82832285	22
11	COSM88514972	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.80G>C	p.C27S	17:82832375-82832375	22
12	COSM138689938	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-889G>C	p.?	17:82832375-82832375	22
13	COSM138689466	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-201C>G	p.?	17:82831687-82831687	22
14	COSM138688764	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-799C>G	p.?	17:82832285-82832285	22
15	COSM88514017	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.777C>A	p.Y259*	17:82831678-82831678	22
16	COSM88515841	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.37C>A	p.H13N	17:82832418-82832418	22
17	COSM138689254	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-192C>A	p.?	17:82831678-82831678	22
18	COSM88514274	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.768C>G	p.Y256*	17:82831687-82831687	22
19	COSM138690667	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-301C>G	p.?	17:82831787-82831787	22
20	COSM138690762	ZNF750	oesophagus,NS,carcinoma,squamous cell carcinoma	c.-229-932C>A	p.?	17:82832418-82832418	22
21	COSM90465117	ZNF548	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1016A>C	p.H339P	19:57399267-57399267	22
22	COSM93683971	ZNF548	oesophagus,NS,carcinoma,squamous cell carcinoma	c.980A>C	p.H327P	19:57399267-57399267	22
23	COSM102366084	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	22
24	COSM102372996	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	22
25	COSM104733716	ZNF365	oesophagus,NS,carcinoma,squamous cell carcinoma	c.712G>A	p.E238K	10:62376905-62376905	22
26	COSM109217250	ZNF230	oesophagus,NS,carcinoma,squamous cell carcinoma	c.87G>C	p.Q29H	19:44008861-44008861	22
27	COSM139548867	ZNF230	oesophagus,NS,carcinoma,squamous cell carcinoma	c.87G>C	p.Q29H	19:44008861-44008861	22
28	COSM100770466	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1117C>T	p.R373W	17:32369340-32369340	22
29	COSM100755139	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1210C>T	p.R404W	17:32369340-32369340	22
30	COSM90696431	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1219C>T	p.R407W	17:32369340-32369340	22
31	COSM139216379	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1210C>T	p.R404W	17:32369340-32369340	22
32	COSM91133838	ZNF207	oesophagus,NS,carcinoma,squamous cell carcinoma	c.1162C>T	p.R388W	17:32369340-32369340	22
33	COSM131330822	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
34	COSM94832002	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
35	COSM88860826	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
36	COSM88887411	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.86A>T	p.E29V	23:152919042-152919042	22
37	COSM89189081	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.71A>T	p.E24V	23:152919042-152919042	22
38	COSM94818098	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
39	COSM129903764	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
40	COSM112129853	ZNF185	oesophagus,NS,carcinoma,squamous cell carcinoma	c.491A>T	p.E164V	23:152919042-152919042	22
41	COSM125164549	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.9439C>T	p.P3147S	8:76863231-76863231	22
42	COSM125167660	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6188C>A	p.P2063H	8:76853187-76853187	22
43	COSM127363671	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.2120C>G	p.S707C	8:76706208-76706208	22
44	COSM127389059	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.10574C>T	p.S3525F	8:76864288-76864288	22
45	COSM127376736	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.4099G>A	p.D1367N	8:76851020-76851020	22
46	COSM127405081	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.439G>T	p.E147*	8:76704527-76704527	22
47	COSM125134824	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6767G>A	p.R2256Q	8:76853766-76853766	22
48	COSM127390973	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.9517C>T	p.P3173S	8:76863231-76863231	22
49	COSM127363056	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.6845G>A	p.R2282Q	8:76853766-76853766	22
50	COSM125162303	ZFHX4	oesophagus,NS,carcinoma,squamous cell carcinoma	c.10496C>T	p.S3499F	8:76864288-76864288	22

Copy number variations for Esophageal Cancer from CNVD:

⁶ (show top 50) (show all 64)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	32702	1	39027237	40780163	Amplification	MYCL	Esophageal cancer
2	35731	1	66691991	71187083	Deletion	CTH	Esophageal cancer
3	38511	10	10309026	19155158	Deletion		Esophageal cancer
4	41416	10	17811791	65388337	Amplification		Esophageal cancer
5	43899	10	50393324	70694787	Deletion		Esophageal cancer
6	48565	11	100815801	103042620	Amplification	BIRC2	Esophageal cancer
7	48566	11	100815801	103042620	Amplification	BIRC3	Esophageal cancer
8	48567	11	100815801	103042620	Amplification	YAP1	Esophageal cancer
9	55251	11	50256798	61426521	Deletion		Esophageal cancer
10	58612	11	68753086	69985447	Amplification	CCND1	Esophageal cancer
11	58613	11	68753086	69985447	Amplification	CTTN	Esophageal cancer
12	58614	11	68753086	69985447	Amplification	FGF19	Esophageal cancer
13	58615	11	68753086	69985447	Amplification	FGF3	Esophageal cancer
14	58616	11	68753086	69985447	Amplification	FGF4	Esophageal cancer
15	58617	11	68753086	69985447	Amplification	MYEOV	Esophageal cancer
16	58701	11	69200000	70700000	Gain	PPFIA1	Esophageal cancer
17	61418	12	1	132078379	Deletion		Esophageal cancer
18	79288	13	68772537	113042980	Deletion		Esophageal cancer
19	80978	14	1	105311216	Deletion		Esophageal cancer
20	83027	14	19100000	23600000	Gain	NFATC4	Esophageal cancer
21	84103	14	23600000	31800000	Gain	ARHGAP5	Esophageal cancer
22	84107	14	23600000	36900000	Gain	PAX9	Esophageal cancer
23	85295	14	42828345	44176016	Deletion		Esophageal cancer
24	111151	17	35097918	35138441	Copy number	ERBB2	Esophageal cancer
25	119155	18	1	1118244	Amplification	TYMS	Esophageal cancer
26	119156	18	1	1118244	Amplification	YES1	Esophageal cancer
27	121678	18	46081464	51919972	Deletion	SMAD4	Esophageal cancer
28	137284	2	141590067	141951947	Deletion	LRP1B	Esophageal cancer
29	151504	20	22140447	26145930	Amplification	PYGB	Esophageal cancer
30	157032	21	1	29932926	Deletion		Esophageal cancer
31	160899	22	16558724	17937900	Amplification	BID	Esophageal cancer
32	160900	22	16558724	17937900	Amplification	CLDN5	Esophageal cancer
33	161388	22	18577713	20667607	Amplification	CRKL	Esophageal cancer
34	161389	22	18577713	20667607	Amplification	MAPK1	Esophageal cancer
35	163870	22	31889314	32003182	Amplification	LARGE1	Esophageal cancer
36	166067	3	1	199344050	Deletion		Esophageal cancer
37	169829	3	14700000	43600000	Loss	RAB5A	Esophageal cancer
38	171482	3	168801287	168851758	Amplification	MECOM	Esophageal cancer
39	171491	3	168867391	169381563	Amplification	MECOM	Esophageal cancer
40	173071	3	189400000	193800000	Gain	TP63	Esophageal cancer
41	174749	3	32100000	54400000	Loss	SCN10A	Esophageal cancer
42	175197	3	3800000	87200000	Loss	ATXN7	Esophageal cancer
43	175734	3	43600000	51400000	Loss	CTDSPL	Esophageal cancer
44	177631	3	59735036	61237133	Deletion	FHIT	Esophageal cancer
45	179189	3	8700000	14700000	Loss	RAF1	Esophageal cancer
46	179592	3	95917505	101945216	Amplification	RIOX2	Esophageal cancer
47	190878	4	91972774	162358674	Deletion	CASP6	Esophageal cancer
48	190879	4	91972774	162358674	Deletion	SMAD1	Esophageal cancer
49	191757	5	10051329	11800765	Amplification	CTNND2	Esophageal cancer
50	198525	5	25700000	76400000	Loss	F2R	Esophageal cancer

Sources

Expression for Esophageal Cancer

Search GEO for disease gene expression data for Esophageal Cancer.

Sources

Pathways for Esophageal Cancer

Pathways directly related to Esophageal Cancer:

#	Pathway	Source
1	Gain-of-function MRAS complexes activate RAF signaling	Reactome ⁶⁶
2	Signaling by MRAS-complex mutants	Reactome ⁶⁶

Pathways related to Esophageal Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	11.46	ZEB2 ZEB1 TP53 TGFBR2
2	miRNAs involved in DNA damage response ⁷⁴	11.26	TP53 MIR373 MIR21
3	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.01	TGFBR2 MIR34A MIR21
4	miRNAs involvement in the immune response in sepsis ⁷⁴	10.72	MIR21 MIR16-2 MIR126 MIR106A
5	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.58	ZEB1 MIR21

Sources

GO Terms for Esophageal Cancer

Cellular components related to Esophageal Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.73	MIR30E MIR21 MIR16-2 MIR148A MIR126 MIR106A
2	extracellular vesicle	GO:1903561	9.1	MIR34A MIR30E MIR21 MIR148A MIR126 MIR106A

Biological processes related to Esophageal Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	9.44	MIR373 MIR34A MIR30E MIR21 MIR16-2 MIR148A
2	negative regulation of vascular endothelial cell proliferation	GO:1905563	9.43	MIR34A MIR30E MIR126
3	negative regulation of vascular endothelial growth factor production	GO:1904046	9.33	MIR373 MIR34A MIR106A
4	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.26	MIR21 MIR148A MIR126 MIR106A

Molecular functions related to Esophageal Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.43	TP53 MIR34A MIR21 MIR126 MIR106A
2	mRNA base-pairing translational repressor activity	GO:1903231	9.17	MIR373 MIR34A MIR30E MIR21 MIR148A MIR126